The NHS has begun rolling out a new form of cancer immunotherapy that allows patients to receive treatment in as little as one minute, marking a significant shift in how some of the most widely used cancer drugs are administered across England.
The injection, a subcutaneous version of pembrolizumab (Keytruda), replaces the traditional intravenous drip that can take between 30 minutes and two hours. According to NHS England, the new approach can reduce treatment time by up to 90%, offering a faster and more convenient option for thousands of patients.
